Evaluation of a Prototype Point-of-care Instrument Based on Monochromatic X-Ray Fluorescence Spectrometry: Potential for Monitoring Trace Element Status of Subjects with Neurodegenerative Disease
Evaluation of a Prototype Point-of-care Instrument Based on Monochromatic X-Ray Fluorescence Spectrometry: Potential for Monitoring Trace Element Status of Subjects with Neurodegenerative Disease
复制标题
DOI：
10.1080/15287394.2012.709412
复制
发表时间：
2012-10
期刊：
影响因子：
--
通讯作者：
K. Mcintosh;M. Cusack;A. Vershinin;Z. Chen;E. Zimmerman;E. Molho;D. Celmins;P. Parsons
中科院分区：
文献类型：
--
作者：
K. Mcintosh;M. Cusack;A. Vershinin;Z. Chen;E. Zimmerman;E. Molho;D. Celmins;P. Parsons
对神经退行性疾病（如阿尔茨海默病（AD）和帕金森病（PD））患者体内的铜（Cu）、锌（Zn）和硒（Se）等微量元素进行评估，可能有助于病因研究以及评估患这些疾病的风险。组装了一台基于单色X射线荧光（M - XRF）的即时检测（POC）原型仪器，并对其在全血、血浆和尿液中测定铜、锌和硒的能力进行了评估。该原型仪器使用血清/血浆中铜和锌的有证标准物质进行了验证，所报告的偏差和相对不精密度均<10%。使用从阿尔茨海默病和帕金森病患者身上采集的人体样本进一步评估了M - XRF原型仪器的性能，发现其在监测血浆和全血中铜和锌水平方面令人满意（偏差<20%）。然而，原型M - XRF的灵敏度不足以对尿液中的铜、锌或硒进行定量。尽管如此，在验证原型仪器时，从19名阿尔茨海默病患者、23名帕金森病患者和24名对照者身上采集了体液（全血、血浆和尿液），专门使用基于电感耦合等离子体质谱（ICP - MS）且经过充分验证的方法进行微量元素分析。这项有限的生物监测研究为血浆、全血和尿液中的多达16种元素（包括锑（Sb）、砷（As）、钡（Ba）、镉（Cd）、铯（Cs）、钴（Co）、铬（Cr）、铜、汞（Hg）、铅（Pb）、钼（Mo）、硒、铊（Tl）、锡（Sn）、锌和铀（U））提供了可靠的数据。尽管样本量有限，但结果并未表明阿尔茨海默病或帕金森病患者与对照组之间在所研究的大多数微量元素方面存在任何显著差异。发现帕金森病患者血浆中的硒相对于阿尔茨海默病患者有统计学上的显著增加，但这可能是由于年龄差异所致。
Assessment of trace elements such as Cu, Zn, and Se in patients with neurodegenerative disease, such as Alzheimer's (AD) and Parkinson's disease (PD), may be useful in etiologic studies and in assessing the risk of developing these conditions. A prototype point-of-care (POC) instrument based on monochromatic x-ray fluorescence (M-XRF) was assembled and evaluated for the determination of Cu, Zn, and Se in whole blood, plasma, and urine. The prototype instrument was validated using certified reference materials for Cu and Zn in serum/plasma, and the reported bias and relative imprecision were <10%. The M-XRF prototype performance was further assessed using human specimens collected from AD and PD subjects, and was found to be satisfactory (<20% bias) for monitoring Cu and Zn levels in plasma and whole blood. However, the prototype M-XRF sensitivity was not sufficient for quantifying Cu, Zn, or Se in urine. Nonetheless, while validating the prototype instrument, body fluids (whole blood, plasma, and urine) were collected from 19 AD patients, 23 PD patients, and 24 controls specifically for trace element analysis using well-validated methods based on inductively coupled plasma mass spectrometry (ICP-MS). This limited biomonitoring study provided robust data for up to 16 elements including Sb, As, Ba, Cd, Cs, Co, Cr, Cu, Hg, Pb, Mo, Se, Tl, Sn, Zn, and U in plasma, whole blood, and urine. The results did not indicate any significant differences in most trace elements studied between AD or PD patients compared to controls, although the sample size is limited. A statistically significant increase in plasma Se was identified for PD patients relative to AD patients, but this could be due to age differences.